Case Reports in Oncology最新文献

{"title":"Olfactory Groove Meningioma Detected 10 Months after Cranial Radiotherapy in a Metastatic Ewing Sarcoma Survivor: A Case Report.","authors":"Ahmad M Al Malla, Ahmad Al-Bitar, Anas Bitar, Maher Saifo","doi":"10.1159/000552787","DOIUrl":"10.1159/000552787","url":null,"abstract":"<p><strong>Introduction: </strong>Secondary intracranial neoplasms are a well-recognized late complication of cranial radiotherapy. Among these, meningiomas are the most frequently reported radiation-associated tumors. However, olfactory groove meningiomas (OGMs) are uncommon, and their development after cranial irradiation with a very short latency remains exceptionally rare.</p><p><strong>Case presentation: </strong>A 38-year-old woman with Ewing sarcoma of the right thigh and brain metastases underwent multimodal treatment of surgical resection, VDC-IE chemotherapy, and subsequent cranial radiotherapy (54 Gy in 27 fractions). Retrospective review of pre-radiotherapy brain MRI showed no lesion in the olfactory groove region. Ten months after completing treatment, she presented with progressive headache, recurrent vomiting, and generalized seizures. Brain CT and MRI revealed a well-circumscribed, homogeneously enhancing extra-axial mass centered at the olfactory groove, with dural attachment and compression of the frontal lobes. Gross-total microsurgical resection was achieved through a right-sided pterional craniotomy. Histopathological examination confirmed a WHO grade I meningioma with diffuse SSTR2A expression, focal epithelial membrane antigen positivity, and a Ki-67 labeling index of 2%-3%. Immunohistochemistry was negative for CD99 and FLI1, excluding metastatic Ewing sarcoma. The postoperative course was uneventful, and follow-up imaging at 1 year showed no evidence of recurrence.</p><p><strong>Conclusion: </strong>This case highlights a rare early-onset OGM arising after cranial radiotherapy in a metastatic Ewing sarcoma survivor. Although the unusually short latency interval precludes definitive causal attribution, the temporal association, absence of a preexisting lesion on pre-radiotherapy imaging, and distinct histopathological profile support consideration of a radiation-associated origin. Long-term neuro-oncologic surveillance remains essential in patients treated with cranial irradiation.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"969-977"},"PeriodicalIF":0.7,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13395415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Pazopanib for a Patient with <i>FGFR1</i>-Amplified Breast Cancer: A Case Report.","authors":"Yurina Ochiai, Saori Hayashi, Emiko Hiraoka, Takafumi Morisaki, Yoshiki Otsubo, Chiaki Nakahara, Yo Sato, Kimihisa Mizoguchi, Yuichi Hisamatsu, Mamoru Ito, Eishi Baba, Natsuko Okita, Makoto Kubo","doi":"10.1159/000552744","DOIUrl":"10.1159/000552744","url":null,"abstract":"<p><strong>Introduction: </strong>Fibroblast growth factor receptor 1 (<i>FGFR1</i>) amplification is associated with endocrine therapy resistance and a poor prognosis in hormone receptor-positive breast cancer. However, effective therapeutic options for <i>FGFR1</i> amplification remain limited. We report a patient with metastatic breast cancer who was treated with pazopanib for <i>FGFR1</i> amplification in the BELIEVE trial.</p><p><strong>Case presentation: </strong>A 71-year-old woman was diagnosed with bilateral luminal-HER2 type breast cancer (pT2N1M0) 18 years previously, and underwent bilateral mastectomy and axillary lymph nodes dissection followed by adjuvant therapy. She had no family history. She developed bone and liver metastases 4 years after the operation and her condition became worse, despite multiple lines of endocrine and cytotoxic therapies. She was treated with pazopanib under the trial because comprehensive genomic profiling showed <i>FGFR1</i> amplification. After 3 months, computed tomography demonstrated necrosis and shrinkage of liver metastases, consistent with a partial response. Serum tumor markers (CEA and CA15-3) showed a sustained decline, reaching their lowest levels at approximately 5 months, consistent with radiologic response. Treatment was continued for 8 months until tumor markers increased and imaging revealed disease progression. Adverse events were manageable.</p><p><strong>Conclusion: </strong>Pazopanib is likely to have a clinical benefit for patients with <i>FGFR1</i>-amplified breast cancer using genomic profiling in personalized oncology at the early stage of metastasis.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1029-1034"},"PeriodicalIF":0.7,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13412246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Segment Malignant Tracheal Stenosis from Recurrent Medullary Thyroid Carcinoma Successfully Palliated with a Covered Self-Expanding Metallic Stent: A Case Report.","authors":"Mohammad Alaa Aldakak, Yousef Al Jabban, Mohammad Shbat, Mohammad Ali Makki, Ahmed Nabhan, Bassam Darwish","doi":"10.1159/000552789","DOIUrl":"10.1159/000552789","url":null,"abstract":"<p><strong>Background: </strong>Medullary thyroid carcinoma (MTC) may rarely cause malignant central airway obstruction (MCAO) through locoregional tracheal invasion, requiring urgent multidisciplinary management. In unresectable thyroid cancer-related MCAO, interventional bronchoscopy with airway stenting can provide rapid restoration of airway patency and symptomatic palliation.</p><p><strong>Case presentation: </strong>A 58-year-old nonsmoking woman with a history of MTC treated with total thyroidectomy and adjuvant radiotherapy presented with progressive exertional dyspnea, productive cough, intermittent mild stridor, and recurrent respiratory infections. She was tachycardic and tachypneic but maintained oxygen saturation on room air. Physical examination revealed a firm, fixed mass in the thyroid bed region. Laboratory investigations showed mild anemia and thrombocytosis. Computed tomography demonstrated approximately 5 cm of tracheal involvement with critical luminal narrowing, consistent with malignant tracheal stenosis from suspected locoregional recurrence. Tracheal biopsy revealed high-grade carcinoma considered clinically compatible with recurrence, although immunohistochemistry and RET mutation testing were unavailable. The disease was deemed unresectable due to local invasion involving the trachea and carotid sheath. Because systemic targeted therapy was not locally available, urgent airway palliation was prioritized. A covered self-expanding metallic tracheobronchial stent was placed successfully across the stenotic segment, resulting in meaningful improvement in breathing and phonation.</p><p><strong>Conclusion: </strong>Covered metallic airway stenting is an effective palliative option for long-segment unresectable malignant tracheal stenosis caused by recurrent MTC, particularly when systemic targeted therapy is unavailable and rapid airway stabilization is required.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"926-932"},"PeriodicalIF":0.7,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13363140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained Disease Control of High-Risk Metastatic Renal Epithelioid Angiomyolipoma through Multimodal Treatment Including Repeated Thoracic Resection and Systemic Therapy: A Case Report.","authors":"Seiji Omura, Jun Hagiuda, Naoko Izawa, Aya Sasaki, Ken Nakagawa, Keisuke Eguchi","doi":"10.1159/000552721","DOIUrl":"10.1159/000552721","url":null,"abstract":"<p><strong>Introduction: </strong>Renal epithelioid angiomyolipoma (EAML) is a rare perivascular epithelioid cell tumor with malignant potential. Radiologic distinction from renal cell carcinoma (RCC) may be difficult in fat-poor cases, and standardized treatment strategies for metastatic disease have not been established.</p><p><strong>Case presentation: </strong>A woman in her 30 s presented with a palpable right abdominal mass and anorexia. Contrast-enhanced computed tomography showed an 18-cm heterogeneous right renal mass and a 25-mm liver lesion suspicious for metastasis, without pulmonary metastasis at diagnosis. The pretreatment clinical stage was cT2bN0M1, stage IV. Imaging findings strongly suggested clear cell RCC, and the lesion was managed as presumed metastatic clear cell RCC. The International Metastatic RCC Database Consortium risk category was poor risk. Nivolumab plus cabozantinib was initiated without pretreatment biopsy. At Month 3, the primary tumor showed partial response and the liver lesion remained stable; however, cabozantinib became difficult to continue because of adverse effects, and right nephrectomy was performed in a setting analogous to deferred cytoreductive nephrectomy. Histopathology established renal EAML with pT2b disease, necrosis, mitotic count ≥2, atypical mitoses, severe nuclear atypia, smooth muscle actin negativity, and Ki-67 ≥ 10%, fulfilling six of seven adverse prognostic factors and indicating high-risk disease. Everolimus induced partial response of a new lung metastasis. Subsequent liver and bilateral lung metastases were managed with systemic therapy and staged thoracoscopic resections. Later, isolated subcarinal mediastinal lymph node progression was treated by thoracoscopic resection. The patient remains recurrence-free for 8 months on everolimus.</p><p><strong>Conclusion: </strong>Metastatic renal EAML lacks a standardized treatment strategy. This case suggests that durable disease control may be achievable in selected high-risk patients through individualized multimodal treatment integrating systemic therapy with repeated local treatment for thoracic oligoprogressive lesions.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"918-925"},"PeriodicalIF":0.7,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13363133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disguised Within: Ectopic Intrathyroidal Parathyroid - A Case Report.","authors":"Chun He, Zhaofei Zeng, Yun Peng, Xianhua Zhuo","doi":"10.1159/000552718","DOIUrl":"10.1159/000552718","url":null,"abstract":"<p><strong>Introduction: </strong>Secondary hyperparathyroidism is prevalent among individuals with chronic kidney failure and is frequently associated with the occurrence of one or more instances of parathyroid hyperplasia. The presence of ectopic parathyroid glands poses significant challenges for the diagnosis and management of affected patients. Intra-adenomatous ectopic parathyroid glands are exceedingly rare, and their preoperative diagnosis using conventional methods is challenging.</p><p><strong>Case presentation: </strong>In this paper, we present a case of a 32-year-old male patient who underwent surgical treatment for secondary hyperparathyroidism. During the operation, an ectopic intrathyroidal parathyroid adenoma was found to mimicked a thyroid nodule. We analyzed the clinical characteristics of these patients and proposed precautions and treatment plans by a comprehensive literature review and analysis.</p><p><strong>Conclusion: </strong>The findings offer valuable insights for the diagnosis and treatment of similar cases and aim to enhance clinicians' understanding of this condition.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"911-917"},"PeriodicalIF":0.7,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13363137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Dysfunction Induced by Pembrolizumab: Five Case Reports.","authors":"Tingting Zhang, Jing Li, Junru Cai, Xiang Li, Lu Lin","doi":"10.1159/000552474","DOIUrl":"10.1159/000552474","url":null,"abstract":"<p><strong>Introduction: </strong>Although pembrolizumab, as a programmed cell death receptor-1 (PD-1) inhibitor, has revolutionized cancer therapy, it is frequently accompanied by immune-related adverse events. Thyroid dysfunction represents a common irAE, yet its clinical trajectory, optimal management approaches, and long-term outcomes remain incompletely characterized.</p><p><strong>Case presentation: </strong>We conducted a retrospective analysis of 5 cancer patients who developed thyroid dysfunction following pembrolizumab therapy. All patients ultimately progressed to hypothyroidism, manifesting heterogeneous patterns: biphasic thyroid dysfunction, persistent hypothyroidism, and delayed presentation after treatment cessation. Patients with baseline positivity for thyroid antibodies (thyroglobulin/thyroid peroxidase antibodies) and elevated thyrotropin levels demonstrated higher susceptibility to severe hypothyroidism. Longitudinal follow-up revealed that thyroid function achieved stabilization following early initiation of hormone replacement therapy, whereas delayed intervention was associated with increased requirements for hormone dose titration.</p><p><strong>Conclusion: </strong>Thyroid dysfunction induced by pembrolizumab is characterized by diverse clinical manifestations and heterogeneous timing of onset. Combination regimens and baseline thyroid status may be significantly associated with its course. Re-treatment risk assessment and dynamic monitoring during therapy should be strengthened in clinical practice as early intervention may improve patient outcomes.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"933-942"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13363141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Cancer Treated with 5-Fluorouracil following Discontinuation of Adjuvant S1 plus Docetaxel and Capecitabine plus Oxaliplatin due to Drug-Induced Acute Pancreatitis: A Case Report.","authors":"Yumi Takamori, Yu Aoki, Hiroaki Miyake, Yumi Amano, Kota Tanuma, Atsushi Nakazawa, Shota Hoshino, Fumiki Toriumi, Shigemichi Hirose, Shinsuke Funakoshi","doi":"10.1159/000552401","DOIUrl":"10.1159/000552401","url":null,"abstract":"<p><strong>Introduction: </strong>Drug-induced acute pancreatitis (DIAP) is a rare cause of acute pancreatitis, accounting for approximately 3-5% of cases, and reports of chemotherapy-induced pancreatitis remain limited.</p><p><strong>Case presentation: </strong>Herein, we present the case of a 68-year-old man who developed DIAP during adjuvant chemotherapy with S-1 plus docetaxel and later with capecitabine plus oxaliplatin following surgery for gastric cancer. A drug-induced lymphocyte stimulation test (DLST) was conducted to identify the suspected agents, yielding positive results for S-1 and capecitabine, whereas docetaxel and oxaliplatin were negative. Unexpectedly, the DLST result for 5-fluorouracil was negative. Based on these findings, adjuvant chemotherapy was switched to 5-fluorouracil plus leucovorin, which was successfully continued without recurrence of pancreatitis. Shortly thereafter, the patient was diagnosed with recurrent gastric cancer. However, palliative chemotherapy with a 5-fluorouracil-based regimen was safely continued.</p><p><strong>Conclusion: </strong>Although DIAP can be fatal, the DLST may help identify the suspected causative drug and contribute to decision-making in important clinical situations such as cancer treatment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"874-881"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response in Metastatic Rectal Cancer with Hepatic and Pulmonary Metastases Treated with Second-Line FOLFIRI plus Ramucirumab: A Case Report.","authors":"Makoto Hasegawa, Hirokazu Okayama, Yuki Kitabori, Naoto Yamauchi, Takahiro Nakajima, Susumu Matsumoto, Naoki Sato, Motonobu Saito, Koji Kono","doi":"10.1159/000551538","DOIUrl":"10.1159/000551538","url":null,"abstract":"<p><strong>Introduction: </strong>In metastatic colorectal cancer (CRC), achieving complete response (CR) through chemotherapy alone is exceedingly rare. We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy.</p><p><strong>Case presentation: </strong>A 61-year-old woman was diagnosed with stage IVB rectal cancer with synchronous liver, lung, and lateral lymph node metastasis (<i>KRAS/BRAF</i> wild-type, microsatellite stable, and HER2-negative). Following first-line FOLFOX plus panitumumab, regression was observed in the rectal lesion and liver metastasis, but one pulmonary nodule progressed. The regimen was switched to second-line FOLFIRI plus ramucirumab. Subsequently, a complete radiological response was observed in all lesions, and a biopsy of the rectal scar confirmed no malignancy. Considering the tumor heterogeneity and surgical morbidity, we engaged in shared decision-making with the patient and adopted a watch-and-wait strategy. The patient received consolidation chemotherapy and remains recurrence-free for 6 months after achieving CR.</p><p><strong>Conclusion: </strong>We report a rare case in which second-line FOLFIRI plus ramucirumab led to a CR in metastatic CRC, even after progression on anti-epidermal growth factor receptor therapy. In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"704-711"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing Teratoma Syndrome Arising from a Pineal Mixed Germ Cell Tumor in a 12-Year-Old Boy.","authors":"Mandana Tasbihi, Guive Sharifi, Sahar Arbab Solimani, Morteza Ashrafi, Mahyar Nourian, Naghmeh Zamani, Alireza Sadeghipour, Bahar Moeini","doi":"10.1159/000552514","DOIUrl":"10.1159/000552514","url":null,"abstract":"<p><strong>Introduction: </strong>Pineal region tumors in children are rare and present significant diagnostic and therapeutic challenges due to their deep location, varied histology, and overlapping radiologic features. Mixed germ cell tumors (MGCTs) are particularly rare and may demonstrate complex clinical behavior.</p><p><strong>Case presentation: </strong>We report the case of a 12-year-old boy who presented in August 2024 with progressive headache and nausea. Brain magnetic resonance imaging (MRI) revealed a large pineal mass. Biopsy with endoscopic third ventriculostomy revealed an MGCT composed of 90% immature teratoma and 10% germinoma, with a Ki-67 index of 25%. Serum alpha-fetoprotein (AFP) was mildly elevated (23.2 ng/mL), while beta-human chorionic gonadotropin levels were normal. The patient received six cycles of chemotherapy according to the ACNS1123 protocol for non-germinomatous germ cell tumors. The MRI after chemotherapy showed increased tumor size with cystic/necrotic components and normalization of AFP. Subsequent surgical resection revealed a mature teratoma without malignant elements, consistent with growing teratoma syndrome (GTS). Notably, the Ki-67 index had decreased from 25% at diagnosis to 5% after resection. Given the initial histology and lack of cerebrospinal fluid analysis, adjuvant craniospinal irradiation of 36 Gy with a 54-Gy boost to the tumor bed was delivered according to ACNS0122.</p><p><strong>Conclusion: </strong>The patient tolerated treatment well and remains in good clinical and radiological condition. This case underscores the importance of recognizing GTS and individualizing treatment in pediatric pineal MGCTs.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"950-958"},"PeriodicalIF":0.7,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13391081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accelerated Bilateral Cataract Progression during Olaparib plus Bevacizumab Maintenance Therapy for High-Grade Serous Fallopian Tube Carcinoma: A Case Report.","authors":"Wataru Saito, Kuniaki Ota, Hana Okamoto, Mitsuru Shiota, Koichiro Shimoya, Yoshiaki Ota","doi":"10.1159/000551721","DOIUrl":"10.1159/000551721","url":null,"abstract":"<p><strong>Background: </strong>Primary peritoneal carcinoma and high-grade serous fallopian tube carcinoma share histopathologic and molecular characteristics with high-grade serous ovarian carcinoma and are treated according to similar therapeutic principles. Poly (ADP-ribose) polymerase (PARP) inhibitors, particularly olaparib, have become central to maintenance therapy, frequently administered with the anti-VEGF agent bevacizumab. Although olaparib is generally well tolerated, ocular toxicities such as cataract formation have not been documented in clinical trials or pharmacovigilance reports, and detailed descriptions are lacking.</p><p><strong>Case presentation: </strong>We report a 66-year-old woman with FIGO stage IIIC high-grade serous carcinoma of the fallopian tube with BRCA mutation and homologous recombination deficiency. After neoadjuvant chemotherapy with paclitaxel, carboplatin, and bevacizumab, followed by interval debulking surgery and postoperative chemotherapy, she achieved a complete response and began maintenance therapy with bevacizumab plus olaparib. After three cycles, she developed rapidly progressive visual impairment in the right eye. Ophthalmologic evaluation revealed a hypermature (Morgagnian-type) cataract with partial liquefaction requiring phacoemulsification with intraocular lens implantation. At the initial ophthalmologic examination, a contralateral mature cataract was also identified but was asymptomatic. Approximately 1 month after right eye surgery, the left eye developed symptomatic visual decline, necessitating cataract extraction. Postoperative recovery of both eyes was excellent.</p><p><strong>Discussion: </strong>To our knowledge, this is the first report describing bilateral accelerated cataract progression during olaparib therapy, particularly in combination with bevacizumab. While causality cannot be confirmed, the rapid onset, bilateral involvement, and temporal association with therapy suggest a potential treatment-related effect. Possible mechanisms include cytokine dysregulation, oxidative stress, and exacerbation of subclinical lens pathology.</p><p><strong>Conclusion: </strong>This case highlights a previously unreported ocular adverse event associated with combined PARP inhibitor and anti-VEGF maintenance therapy. Clinicians should maintain vigilance for visual symptoms and consider periodic ophthalmologic monitoring in patients receiving prolonged olaparib-based therapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"796-804"},"PeriodicalIF":0.7,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13290137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}